General Information
Theracos DM2/Cardiac C-476
A Double-Blind Placebo-Controlled Study to Evaluate the Effects of Bexagliflozin on Hemoglobin A1c in Patients with Type 2 Diabetes and Increased Risk of Cardiovascular Adverse Events.
| Protocol | THR-1442-C-476 |
|---|---|
| Identifier | |
| UID | 100db2e2-0099-40b1-aef4-d0e8f92fa908 |
| Status | Done - Archived |
| Phase | 3 |
| Category | Diabetes Type 2 / Adult |
| Launch Year | 2016 |
| NCT Number | - |
| Created | 2015-09-01 12:27 |
| Last Updated | 2015-09-01 12:27 |
Description
No description provided.
Comment
CRI
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2016-08-18 | No |
| Enrollment Open | 2016-01-11 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2015-12-02 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2020-01-07 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Casaclang, Cecilia | CCasaclang | No |
| Recruiter | - | No | |
| Coordinator | Rocha, Luis | LRocha | No |
| Regulatory | Perez, Myrna | MPerez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Theracos Sub, LLC |
|---|---|
| Division | Theracos Sub, LLC |
| Team | Theracos Sub, LLC |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | Covance -LabCorp Drug Development |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
